New drug cocktail shows promise for Tough-to-Treat myeloma

NCT ID NCT02199665

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This early-phase study tested a combination of three drugs (selinexor, carfilzomib, and dexamethasone) in 52 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and identify side effects. Researchers also looked at whether the treatment could shrink or control the cancer. This is not a cure, but a way to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic (AZ)

    Scottsdale, Arizona, 85259, United States

  • Mount Sinai Medical Center

    New York, New York, 10029, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • Wayne State University Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

Conditions

Explore the condition pages connected to this study.